References
- Anonymous (2005). Effects of chemotherapy and hormonal therapy for early breast cancer on reccurrence and 15-year survival: An overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Lancet, 365 (9472), 1687-1717.
- De Laurentiis, M., Caputo, F., Massarelli, E., Forestieri, V., Vernaglia, A., Carlomagno, C., Lauria, R., Bianco, A. R., De Placido, S. (2001). HER2 expression and anthracycline effect: Results from the Naple GUN 3 randomized trial. Proc. Am. Soc. Clin. Oncol., 20, 34A (abstract 133).
- Dressler, L. G., Berry, D. A., Broadwater, G., Cowan, D., Cox, K., Griffin, S., Miller, A., Tse, J., Novotny, D., Persons, D. L., Barcos, M., Henderson, I. C., Liu, E. T., Thor, A., Budman, D., Muss, H., Norton, L., Hayes, D. F. (2005). Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients. J. Clin. Oncol., 23(19), 4287-4297.
- Gusterson, B. A., Gelber, R. D., Goldhirsch, A., Price, K. N., Save-Soderborgh, J., Anbazhagan, R., Styles, J., Rudenstam, C. M., Golouh, R., Reed, R. (1992). Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J. Clin. Oncol., 10(7), 1049-1056.
- Harris, L. N., Yang, L., Liotcheva, V., Pauli, S., Iglehart, J. D., Colvin, O. M., Hsieh, T. S. (2001). Induction of topoisomerase II activity after Erb B2 activation is associated with a differential response to breast cancer chemotherapy. Clin. Cancer Res., 7(6), 1497-1504.
- Jarvinen, T. A., Liu, E. T. (2003). HER-2/neu and topoisomerase IIalpha in breast cancer. Breast Cancer Res. Treat., 78(3), 299-311.
- Jarvinen, T. A. H., Tanner, M., Rantonen, V., Barlund, M., Borg, A., Grénman, S., Isola, J. (2000). Amplification and deletion of topoisomerase II associate with Erb B-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Amer. J. Pathol., 156(3), 839-847.
- Knoop, A. S., Knudsen, H., Balslev, E., Rasmussen, B. B., Overgaard, J., Nielsen, K. V., Schonau, A., Gunnarsdottir, K., Olsen, K. E., Mouridsen, H., Ejlertsen, B. (2005). Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil. J. Clin. Oncol., 23(30), 7483-7490.
- Konecny, G., Fritz, M., Untch, M., Lebeau, A., Felber, M., Lude, S., Beryt, M., Hepp, H., Slamon, D., Pegram, M. (2001). HER-2/neu overexpression and in vitro chemosensitivity to CMF and FEC in primary breast cancer. Breast Cancer Res. Treat., 69(1), 53-63.
- Levine, M. N., Bramwell, H., Pritchard, K. I., Shepherd, L. E., Tu, D., Paul, N. (1998). Randomised trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. J. Clin. Oncol., 16(22), 2651-2658.
- Paik, S., Bryant, J., Park, C., Fisher, B., Tan-Chiu, E., Hyams, D., Fisher, E. R., Lippman, M. E., Wickerham, D. L., Wolmark, N. (1998). erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J. Natl. Cancer Inst., 90(18), 1361-1370.
- Pegram, M. D., Finn, R. S., Arzoo, K., Beryt, M., Pietras, R. J., Slamon, D. J. (1997). The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene, 15(5), 537-547.
- Pinder, M. C., Duan, Z., Goodwin, J. S., Hortobagyi, G. N., Giordano, S. H. (2007). Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J. Clin. Oncol., 25(25), 3808-3815.
- Pritchard, K. I., Shepherd, L. E., O'Malley, F. P., Andrulis, I. L., Tu, D., Bramwell, V. H., Levine, M. N. (2006). HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N. Engl. J. Med., 354(20), 2103-2111.
- Slamon, D. J., Godolphin, W., Jones, J. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., Press, M. F. (1989). Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science, 244(4905), 707-712.
- Wolff, A. C., Hammond, M. E. H., Schwartz, J. N., Hagerty, K. L., Allred, D. C., Cote, R. J., Dowsett, M., Fitzgibbons, P. L., Hanna, W. M., Lager, A., McShane, L. M., Paik, S., Pegram, M. D., Perez, E. A., Press, M. F., Rhodes, A., Sturgeon, C., Taube, S. E., Tubbs, R., Vance, G. H., van de Vijver, M., Wheeler, T. M., Hayes, D. F. (2007). American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer. J. Clin. Oncol., 25(1), 118-145.